Between 2010 and 2014, 37 new molecular entities were approved by the FDA for the treatment of cancer; and between 1995 and 1999, only 20 such agents were approved. Michael Kurman, MD, from INC Research shares his thoughts on Phase 1 Clinical Trials in an Era of Increasing Oncologic Success.